IRD

#3308
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
3.69
3.69
Range Annuel
2.82
5.81
Changement quotidien
-4.16%
Changement Mensuel
+6.65%
Evolution sur 6 mois
-9.56%
Changement Annuel
-0.81%
Clôture Précédente
3.8 5
Open
3.6 9
Low
3.6 9
High
3.6 9
Volume
59
Afficher le graphique complet

Financials

Aperçu Relevé Statistiques Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, 09 June 2016

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on June 9, 2016. The filing documents the results of the Company's 2016 Annual Meeting of Shareholders held on that date.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.

Material Changes and Voting Results

Shareholders approved three key proposals at the Annual Meeting. On the record date, there were 213,173,785 shares outstanding, with 153,062,321 shares present or represented by proxy.

  • Proposal 1 (Election of Directors): All seven nominees were elected to one-year terms. Significant broker non-votes (83,692,088) were recorded for each nominee.
  • Proposal 2 (Ratification of Auditors): Baker Tilly Virchow Krause, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2016. Votes: 130,898,861 For, 4,983,500 Against, 17,179,960 Abstain.
  • Proposal 3 (Stock Option Plan Amendment): Shareholders approved the amendment and restatement of the 2013 Stock Option Plan to include awards of restricted stock or restricted stock units. Votes: 48,512,254 For, 5,736,371 Against, 15,121,608 Abstain.

Guidance, Outlook, and Risks

The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors. The primary disclosure relates to the successful amendment of the Company's equity compensation plan.

Investor Verification Checklist

  • Verify the exact terms of the Amended and Restated 2013 Stock Option Plan (Exhibit 10.1) to understand the new restricted stock unit provisions.
  • Review the Definitive Proxy Statement filed on April 18, 2016, for detailed descriptions of the proposals and director biographies.
  • Note the high volume of broker non-votes (approx. 83.7 million shares) on the director election, indicating a significant portion of shares were not voted on this specific proposal.
  • Confirm the Company's name is Rexahn Pharmaceuticals, Inc., as the input metadata referenced Opus Genetics, Inc. incorrectly.